BioMarin Pharmaceutical Inc (BMRN)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 33% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- QualityRevenue growing 11% y/y+1
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst: earnings, driven by the Q2 beat and raised 2026 guidance on strong Voxzogo sales. Continuation probability is moderate-to-high (roughly 60-65%) given the positive momentum and analyst reaffirmation, though conference chatter adds limited new fuel. Informational only — not financial advice.
- BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeekingAlpha · 2026-08-12
- BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in BostonYahoo · 2026-08-10
- Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114Benzinga · 2026-08-10
- BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook RaisedYahoo · 2026-08-07
- BioMarin Lifts 2026 Outlook on Strong Voxzogo Sales, Wedbush SaysYahoo · 2026-08-07
Any AI summary is an interpretation of public news, not advice or a price target.